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Summary
Formation of cerebral oedema caused by vascular leak-
age is a major problem in various injuries of the CNS,
such as stroke, head injury and high-altitude illness. A
common feature of all these disorders is the fact that
they are associated with tissue hypoxia. Hypoxia has
therefore been suggested to be an important pathogenic
factor for the induction of vascular leakage in the
brain. Vascular endothelial growth factor (VEGF) is
known as the major inducer of angiogenesis. Originally,
however, it was described as a vascular permeability
factor. As VEGF gene expression was shown to be up-
regulated by hypoxia, increased VEGF expression may
link hypoxia and vascular leakage in the CNS in vivo.
To delineate the role of VEGF in vascular leakage in
the brain, we studied the effect of hypoxia on VEGF
expression and vascular permeability in the brains of
mice in vivo. Hypoxic exposure led to a signi®cant
increase in the levels of VEGF mRNA and protein in
mouse brain that correlated with the severity of the
hypoxic stimulus. Measurement of vascular permeabil-
ity using the ¯uorescent marker sodium ¯uorescein
revealed a two-fold increase in ¯uorescence intensity in
hypoxic brains, indicative of signi®cant vascular leak-
age. Inhibition of VEGF activity by a neutralizing anti-
body completely blocked the hypoxia-induced increase
in vascular permeability. In conclusion, our data show
that VEGF is responsible for hypoxia-induced augmen-
tation in vascular leakage following tissue hypoxia. Our
®ndings might provide the basis for new therapeutic
concepts for the treatment of cerebral oedema.
Keywords: vascular permeability; oedema; VEGF; HACE; ischaemia
Abbreviations: BBB = blood±brain barrier; HACE = high-altitude cerebral oedema; HIF = hypoxia-inducible factor; r.f.u.
= relative ¯uorescence unit; VEGF = vascular endothelial growth factor
Introduction
Oedema formation is a major life-threatening complication of
various injuries of the CNS, such as head injury (Murakami
et al., 1999; Pilitsis and Rengachary, 2001), tumour growth
(Papadopoulos et al., 2001) and cerebral ischaemia (Lipton,
1999; Rosenberg, 1999). It also occurs during high-altitude
illness (Hackett and Roach, 2001). Acute mountain sickness
and high-altitude cerebral oedema (HACE) refer to cerebral
abnormalities of high-altitude illness and are syndromes that
occur in unacclimatized persons on ascent to high altitude
(Hackett, 1999). Acute mountain sickness is characterized by
the presence of headache, nausea, insomnia, dizziness and
fatigue (Hackett and Roach, 2001) and is probably due to the
formation of mild cerebral oedema (Hackett, 1999). HACE,
clinically de®ned as the onset of ataxia and altered con-
sciousness, has been considered to be the end-stage of acute
mountain sickness, eventually leading to death caused by
brain herniation (Hackett and Roach, 2001). While the
clinical aspects of HACE are well established, its pathophy-
siology remains elusive. Recent evidence suggests that
HACE is associated with osmotic cell swelling, vasogenic
oedema and biochemical alteration of the blood±brain barrier
(BBB) (Severinghaus, 1995; Hackett, 1999; Hackett and
Roach, 2001). Vasogenic brain oedema is de®ned as the
translocation of proteins and ¯uid from the vascular space
across the BBB (Hackett, 1999). The underlying molecular
and pathogenic mechanisms are poorly understood. Several
years ago, Severinghaus and Xu hypothesized that the
vascular endothelial growth factor (VEGF) might be respon-
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 sible for the vascular leakage and oedema formation in
the brain that occurs during high-altitude exposure
(Severinghaus, 1995; Xu and Severinghaus, 1998). VEGF is
the most prominent member of an increasing family of
angiogenic growth factors and plays a key role in new vessel
growth. VEGF is an endothelial mitogen and exists as several
isoforms derived from a single gene by alternative splicing
(Robinson and Singer, 2001). It is ubiquitously expressed,
binds to two endothelial tyrosine receptors, VEGF receptor 1
(VEGFR-1, Flt-1) and VEGFR-2 (Flk-1/KDR), and is also a
ligand for the semaphorin receptors neuropilin 1 and
neuropilin 2 (Robinson and Singer, 2001).
There is good evidence to support the hypothesis of
Severinghaus and Xu. First, all the above-mentioned brain
pathologies involving oedema formation are associated with
tissue hypoxia. For example, hypoxic regions have been
identi®ed around brain tumours (Shweiki et al., 1992; Evans
et al., 1997; Damert et al., 1997; Talks et al., 2000). Also,
during cerebral ischaemia, a region around the core of the
infarctÐthe so-called penumbraÐsuffers from hypoxia
(Evans et al., 1997; Read et al., 1998; Marti et al., 2000).
Finally, at high altitude, reduced ambient pO2 levels result in
systemic tissue hypoxia that also affects the brain. Thus,
tissue hypoxia could play an important role in the pathogen-
esis of vascular leakage leading to brain oedema formation,
e.g. by activating speci®c genes. Secondly, VEGF is among
the best-known of the genes that are induced by hypoxia
(Shweiki et al., 1992; Marti and Risau, 1998). VEGF gene
expression is known to be activated under hypoxic conditions
at the level of transcription, increased stability of the mRNA
and preferential translation (Ikeda et al., 1995; Levy et al.,
1995; Stein et al., 1998). Transcriptional activation is
achieved by the transcription factors hypoxia-inducible
factor 1 (HIF-1) and HIF-2 (Forsythe et al., 1996; Ema
et al., 1997). HIF-1 binds to a hypoxia response element
(HRE) in the 5¢-¯anking region of the VEGF gene, thereby
enhancing transcription of the gene (Forsythe et al., 1996).
Increased VEGF levels in hypoxic tissues are thought to
induce an angiogenic reaction that enables increased delivery
of nutrients and oxygen to the hypoxic cells through newly
formed vessels (Shweiki et al., 1992; Marti and Risau, 1999).
Tissue hypoxia and angiogenesis are thus interdependent, and
have indeed been observed to coincide during cerebral
ischaemia (Marti et al., 2000), tumour growth (Damert
et al., 1997) and chronic hypoxic situations (Harik et al.,
1995; LaManna and Harik, 1997). Thirdly, VEGF is
expressed in the CNS in astrocytes and, after hypoxic
exposure, in neurones (Marti and Risau, 1998; Ogunshola
et al., 2000). Finally, VEGF was originally isolated as a factor
leading to increased vascular permeability in tumours and
was named vascular permeability factor (Senger et al., 1983).
Thus, VEGF might be a signi®cant contributor to hypoxia-
induced vascular leakage and oedema formation in the brain
(Xu and Severinghaus, 1998). If so, inhibition of VEGF
action could prevent brain oedema formation and thus be
useful as a therapeutic strategy to treat patients with HACE
and other diseases associated with oedema formation. We
therefore analysed vascular leakage and expression of VEGF
during systemic normobaric hypoxia in the brains of mice
in vivo and inhibited VEGF action by systemic application of
a neutralizing anti-VEGF antibody.
Material and methods
Animals
All experiments were performed according to protocols
approved by the Regierungspra Èsidium Darmstadt. Adult C57/
BL6 mice were exposed to normobaric hypoxia at 12±6%
oxygen (corresponding to an altitude of 4000±9500 m) for
24 h or were kept at room air pressure. Hypoxia was achieved
by substituting nitrogen for oxygen using a Digamix 5SA 18/
3a pump (H. Wo Èsthoff, Bochum, Germany) after gradual
adaptation over a period of 1 h (Marti and Risau, 1998). Mice
had free access to food and water. Following hypoxic
exposure, the animals were killed by decapitation and the
dissected brains were frozen in liquid nitrogen or embedded
for cryosectioning.
Determination of brain water content and
vascular permeability
To quantify brain water content in brains from normoxic and
hypoxic animals, the wet weights of the brains were
determined immediately after removal. The samples were
dried at 110°C for 24 h and reweighed to give the dry weight.
The difference between the wet and dry weights was taken as
the in vivo water content.
To quantify vascular permeability of brain vessels, 200 ml
of sodium ¯uorescein (Sigma, Taufkirchen, Germany) at a
concentration of 6 mg/ml in PBS (phosphate-buffered saline)
was injected through the tail vein after 24 h of hypoxic or
normoxic exposure. Sodium ¯uorescein (MW 376.3) is a
¯uorescent tracer that does not cross an intact BBB (Williams
et al., 1984). Thirty minutes later, mice were anaesthetized
and then perfused with PBS (20 ml) through the left heart
ventricle to remove the ¯uorescent tracer from the vascular
bed. Subsequently, both hemispheres of the brain were
removed and frozen in liquid nitrogen. To assess ¯uores-
cence, brain hemispheres were homogenized in 0.5 M borate
buffer (pH 10) and centrifuged (3000 r.p.m.) for 15 min at
4°C, and the supernatant was added to 1.2 ml of ethanol to
precipitate proteins. Probes were again centrifuged (13 000
r.p.m.) for 20 min at 4°C and the ¯uorescence of the
supernatant was measured at 485 nm at an excitation
wavelength of 330 nm using a Lambda Fluoro 320
Fluoroscope (MWG Biotech, Ebersberg, Germany) (Baba
et al., 1988). Results are presented as relative ¯uorescence
units (r.f.u.) per mg of brain tissue. In a second set of
experiments, a neutralizing goat anti-mouse VEGF antibody
or a corresponding control goat IgG antibody (R&D Systems,
Minneapolis, MN, USA) was injected intraperitoneally at
2550 H. J. Schoch et al.
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 100 mg (dissolved in 100 ml PBS) immediately prior to the
24 h hypoxic or normoxic exposure.
RNA extraction, Northern blot analysis and in
situ hybridization
Total RNA was extracted using peqGOLD RNA pure (Peqlab
Biotechnologie, Weingarten, Germany) essentially as de-
scribed (Wenger et al., 1996). Northern blot analysis was
performed as described (Marti et al., 1996; Wenger et al.,
1996). Hybridization patterns with RNA for the ribosomal
protein L28, which remains unaffected by hypoxia (Wenger
et al., 1995), were used to correct for loading differences of
total RNA on each lane. To quantify VEGF levels,the relative
intensities for the hybridization signal (VEGF/L28) were
calculated and are presented as percentages of the normoxic
control. VEGF in situ hybridization was performed exactly as
described (Breier et al., 1992; Marti and Risau, 1998).
Mouse VEGF immunoassay
Cortical brain tissue lysates from normoxic and hypoxic
animals were prepared as described (Marti et al., 2000).
Mouse VEGF was quanti®ed using a commercially available
immunoassay kit (Quantikine M; R&D Systems) as described
(Marti et al., 2000).
Presentation of data and statistics
Steady-state mRNA levels for VEGF and L28 were recorded
and quanti®ed using a Bio-Imaging Analyzer (BAS-2500;
Fuji,RaytestGmbH,Straubenhardt,Germany).VEGFsignals
were then normalized to the signal obtained with the L28
cDNA probe to correct for loading and blotting differences.
For hypoxia-inducible expression of VEGF, mRNA and
protein levels were expressed as percentages of the corres-
ponding normoxic control. For the statistical analysis of the
data, means and standard deviations of n experiments were
determined and Student's t-test was performed.
Results
Normobaric hypoxia induces vascular leakage
in the brain
To mimic a stay at high altitude, mice were exposed to
various fractions of inspiratory oxygen in a normobaric
hypoxic chamber for a period of 24 h. To explore whether
exposure to severe hypoxia led to the occurrence of HACE,
we ®rst examined changes in brain water content as a sign of
oedema formation in this organ. Brain water content
increased slightly, but not signi®cantly, from 77.99 6
0.31% (n = 11) in normoxic controls to 78.92 6 1.96
(n = 12) after hypoxic exposure. The small increase observed
might have been due to considerable water loss resulting from
severe hyperventilation, as animals that were exposed for 24 h
to hypoxia lost more than 10% of their body weight, whereas
the normoxic control mice kept their weight constant.
To ®nd out directly whether vascular leakage had occurred
as a result of hypoxic exposure, we quanti®ed vascular
permeability by a direct method. Sodium ¯uorescein was
injectedthrough the tail vein andallowed tocirculate.Sodium
¯uoresceinisa¯uorescence tracerthatcanbemeasuredeasily
in homogenates of brain hemispheres to exactly quantify dye
extravasation and thus vascular permeability.
Relative ¯uorescence intensity in the brain of mice
exposed to 8% oxygen increased more than two-fold
(P < 0.0001) compared with normoxic controls, indicative
of increased vascular leakage of the dye (Fig. 1).
Fluorescence in control brain hemispheres was 31.38 6
4.59 r.f.u./mg brain tissue (n = 30) and increased to 68.70 6
18.97 r.f.u./mg (n = 8) at 8% oxygen. To address the question
whether there is a threshold level above which vascular
permeability is unaffected, we exposed mice in addition to 12
and 10% oxygen. Under both conditions, dye extravasation
was not signi®cantly different from that in normoxic control
animals (12% oxygen, 29.04 6 11.12 r.f.u./mg, n =8 ;1 0 %
oxygen, 33.38 6 12.58 r.f.u./mg, n = 10). Thus, vascular
leakage of ¯uorescent dye during severe hypoxic exposure
suggests that during exposure to 8% oxygen a signi®cant
increase in vascular permeability of cerebral microvessels
occurred. Furthermore, there was a sharp and signi®cant
increase in vascular permeability when animals were exposed
to 8% oxygen compared with exposure to 10% (P < 0.001)
Increased VEGF gene expression in the brain is
dependent on severity of hypoxia
An important question concerns the mechanisms that may
link tissue hypoxia and increased vascular permeability. A
promising candidate is the angiogenic growth factor VEGF.
Fig. 1 Two-fold increase in vascular permeability after exposure
to 8% oxygen. Sodium ¯uorescein injected intravenously in
controls or hypoxic mice was quanti®ed following homogenization
of brain hemispheres. Results are expressed as relative
¯uorescence units (r.f.u.). Values are mean and standard deviation.
**P < 0.0001; *P < 0.001; n = 8±30 as indicated.
Brain vascular leakage caused by VEGF 2551
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 Expression of VEGF mRNA and protein levels in normoxic
and hypoxic brains was therefore analysed using Northern
blotting, in situ hybridization and ELISA (enzyme-linked
immunosorbent assay) techniques. VEGF mRNA was detect-
able by Northern blot analysis in all brain samples tested
(Fig. 2, upper panel). In normoxic brains, though, mRNA
levels were very low, but increased slightly after exposure to
12% oxygen. A signi®cant increase was seen at 10% oxygen,
and mRNA levels rose further at 8 and 6% oxygen (Fig. 2,
lower panel). VEGF mRNA levels did not differ signi®cantly
between 6 and 8% oxygen.
To analyse the regional distribution of VEGF expression
under normoxic and hypoxic conditions, in situ hybridization
experiments were performed. In normoxic controls, VEGF
mRNA expression was very low and was homogeneous
throughout the brain (Fig. 3). Stronger expression was
detected only in the epithelial cells of the choroid plexus,
as described previously (Marti and Risau, 1998). After
hypoxic exposure, levels of VEGF mRNA were clearly
increased all over the cortex, in the hippocampus, cerebellum
and the subventricular zone, whereas expression was dimin-
ished in the choroid plexus. Thus, with the exception of
epithelial cells of the choroid plexus, exposure to hypoxic
hypoxia led to general activation of VEGF gene expression in
the whole brain. Taken together, our results demonstrate a
strong, continuous, oxygen-regulated increase in VEGF gene
expression throughout the brain.
To con®rm these mRNA data at the protein level, we
isolated total cortical proteins and quanti®ed the amount
of VEGF protein present by ELISA. The basal normoxic
level of VEGF was 2.4 6 0.9 ng/g total protein, which
increased to 9.6 6 1.8 and 11.6 6 5.0 ng/g after
exposure to 12 and 10% oxygen, respectively. A signi®-
cant further increase was found at 8% (19.5 6 2.3 ng/g
total protein) and 6% (21.9 6 3.6 ng/g total protein)
oxygen (P < 0.05) (Fig. 4). Again, the VEGF level did
not differ signi®cantly between 6 and 8% oxygen. Thus,
both RNA and protein data con®rm a continuous increase
in VEGF production in the brain when systemic oxygen
availability is decreased progressively. These results
implicate VEGF in the generation of vascular leakage
and brain oedema during episodes of severe tissue
hypoxia.
Blocking VEGF action prevents vascular
permeability
To further test the hypothesis that VEGF confers hypoxia-
related leakage of cerebral blood vessels and may thus be
responsible for the occurrence of HACE, neutralizing anti-
bodies directed against mouse VEGF were applied immedi-
ately before hypoxic exposure by injecting 100 mgo fa
neutralizing goat anti-mouse VEGF antibody intraperitone-
ally. An isotypic goat IgG antibody was used as a speci®c
negative control. As expected from the ®rst round of
experiments, vascular permeability increased after hypoxic
exposure to 8% oxygen, i.e. the r.f.u. level rose from 30.69 6
7.16 (n = 4) in normoxic controls to 58.60 6 15.63 per mg
brain tissue (n = 7) in hypoxic animals (Fig. 5). In sharp
contrast, the hypoxic increase in vascular permeability in
mice treated with VEGF antibody was completely prevented
(29.59 6 3.92 r.f.u./mg, n = 4), demonstrating the causative
relationship between hypoxic VEGF induction and hypoxia-
induced vascular leakage in the brain.
Discussion
This study demonstrates that inhibition of VEGF action is
able to prevent hypoxia-induced vascular leakage inthe brain.
Our data support the hypothesis that exposure to systemic
hypoxia activates VEGF gene transcription in the CNS,
leading to increased VEGF protein levels, which in turn
increase vascular permeability in brain microvessels.
Furthermore, our results demonstrate the existence of a
threshold level at ~10% oxygen at which VEGF expression
starts to increase but no change in vascular permeability is yet
observed. Our ®ndings provide the basis for the treatment of
oedema formation in the CNS that is associated with brain
injury, stroke and HACE.
Fig. 2 Increased expression of VEGF mRNA in mouse brain after
hypoxic stimulation. Total RNA was extracted from brains of
normal mice and mice exposed to 6±12% oxygen for 24 h. (Upper
panel) Northern blots of total RNA sequentially hybridized with a
32P-labelled probe for murine VEGF and the ribosomal protein
L28. (Lower panel) Mean and standard deviation (n = 3) of VEGF
mRNA pixel densities as quanti®ed with a Phosphoimager and
corrected for L28. Normoxic control was set to 100%. **P <
0.001; *P < 0.05; n.s., not signi®cant.
2552 H. J. Schoch et al.
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 Fig. 3 VEGF mRNA expression detected by in situ hybridization on sagittal sections of mouse brain.
Following exposure to 8% oxygen (lower panel), VEGF mRNA is upregulated homogeneously all over
the brain compared with normoxic controls (middle panel). (Upper panel) Hybridization with a VEGF
sense probe. CB = cerebellum; chp = choroid plexus; CTX = cerebral cortex; DG = dentate gyrus; HIP =
hippocampal region; SC = superior colliculus; SEZ = subependymal zone; TH = thalamus; VL = lateral
ventricle.
Brain vascular leakage caused by VEGF 2553
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 Inverse correlation between VEGF expression
and inspired oxygen concentration
We noted that VEGF expression started to increase at ~10%
oxygen, but only after exposure to 8% oxygen were
signi®cant changes in vascular permeability in the brain
microvessels observed, suggestive of the existence of de®ned
threshold levels for VEGF expression and permeability
changes. Activation of VEGF expression during hypoxic
exposure has been investigated in a number of studies,
although these investigated mostly the effects of exposure
time, not variation in oxygen concentration (Patt et al., 1998;
Xu and Severinghaus, 1998; Kuo et al., 1999). Increased
VEGF gene expression is thus found consistently when
inspired oxygen levels fall below 10%, which corresponds to
the amount of oxygen present at ~5300 m altitude. In our
mouse model, vascular leakage was detected only after 24 h
of exposure to 8% oxygen, corresponding to 7100 m altitude.
The occurrence of HACE in humans is increasingly common
and severe at altitudes higher than 4000 m, while the
incidence is clearly reduced at 3000 m (Severinghaus. 1995).
Thus, also in humans there is a clear relation between the
occurrence of HACE symptoms and the degree of hypoxia.
The difference in the degree of hypoxia required to elicit
vascular leakage and oedema formation in humans and mice
might be explained by the fact that in humans it is mostly
clinical symptoms that are considered (Hackett and Roach,
2001), whereas in our mouse model we sought direct proof of
brain vascular leakage. It might also be due to species
differences, since it has been shown that small animals have a
higher capillary density in the muscles compared with larger
species (Schmidt-Nielsen and Pennycuik, 1961). This may
also hold true for the brain, resulting in a shorter diffusion
distance from the capillary to the metabolizing cell, thus
making mice more resistant to hypoxia than man.
VEGF gene expression is transcriptionally regulated by
HIF-1 (Forsythe et al., 1996). We have previously demon-
strated in vitro that HIF-1 activation is inversely related to
oxygen concentration, with a half-maximal activation of HIF
at 1.5±2% oxygen (Jiang et al., 1996). Although we did not
measure pO2 within the brain parenchyma of our mice, data
from the literature suggest that normal tissue pO2 levels in the
brain are in the range of 20 mm Hg (2.5% oxygen) (Whalen
et al., 1970). During hypoxic exposure, levels certainly drop
further, to a range where even small changes in pO2 lead to
strong activation of HIF-1. Indeed, it was shown very recently
that HIF-1 protein accumulated gradually in the brain within
2±6 h when mice were exposed to decreasing amounts of
oxygen ranging from 21 to 6% (Stroka et al., 2001). Thus,
activation of HIF-1 precedes upregulation of VEGF expres-
sion, which will then lead to increased permeability, given a
strong enough hypoxic stimulus.
A clinically important question which arises from our
®ndings that different hypoxic threshold levels exist for the
activation of VEGF gene expression and the induction of
vascular leakage is whether VEGF levels can be used as a
marker to identify patients at risk of developing HACE. As it
is not feasible to analyse brain VEGF levels in humans, one
might look at plasma VEGF levels. In the plasma of our
hypoxic mice (n = 3), we found that VEGF levels were
elevated less than two-fold and non-signi®cantly at both 12
and 8% oxygen (3.9 6 0.63 and 3.7 6 0.57 ng VEGF/ml,
respectively) compared with normoxic controls (2.4 6 0.27
ng VEGF/ml). This result is ingood agreement with a study in
humansdemonstratingnoincreaseinplasmaVEGFat4200m
and no correlation of VEGF with oxygen saturation or
symptoms of acute mountain sickness (Maloney et al., 2000).
Furthermore, in a recent study investigating plasma VEGF
levels in humans at high altitude (4559 m), no correlation
between VEGF and the occurrence of acute mountain
sickness symptoms was found either, although VEGF in the
plasma was signi®cantly increased after hypoxic exposure
(Walter et al., 2001). Thus, as VEGF is a classical paracrine
factor, released by one cell and acting on an adjacent
Fig. 4 Increased VEGF protein levels in the hypoxic brain. The
amount of VEGF protein present in the brain was measured using
an ELISA (enzyme-linked immunosorbent assay) speci®c for
murine VEGF. Values are mean and standard deviation (n = 3).
**P < 0.01; *P < 0.05. Note the inverse correlation between
VEGF protein level and oxygen concentration.
Fig. 5 Blocking VEGF action prevents hypoxia-induced vascular
leakage in the brain. A neutralizing anti-VEGF antibody (aVEGF)
or an isotypic goat antibody (IgG) was injected intraperitoneally
before exposure to 20% (black columns) or 8% oxygen (grey
columns) for 24 h. Vascular permeability was assessed as
described in Figure 2. Values are mean and standard deviation.
*P < 0.01; n = 4±7 as indicated.
2554 H. J. Schoch et al.
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 endothelial cell, systemic VEGF levels do not appear to be
useful for the direct identi®cation of patients at risk of HACE
formation.
Anti-VEGF treatment blocks vascular leakage
VEGF has been considered as a causative agent in HACE
formation, although no direct data were presented (Xu and
Severinghaus, 1998). Our results now show that there is a
direct causative relation between inhibition of VEGF action
and the prevention of hypoxia-induced vascular leakage.
Further indirect evidence is coming from a number of studies
demonstrating a correlation between increased VEGF expres-
sion and oedema formation in brain tumours (Machein and
Plate, 2000) and brain injury (Nag et al., 1997; Papavassiliou
et al., 1997) as well as in cerebral ischaemia (Zhang et al.,
2000). Inhibition of VEGF action has been considered to be
useful in a variety of brain pathologies. An anti-VEGF
strategy is currently being used in various clinical trials to
treat tumour patients with the aim of inhibiting tumour-
induced angiogenesis, thereby depriving the tumour cells of
nutrients and oxygen (Carmeliet and Jain, 2000). Anti-VEGF
treatment may have, in addition, a bene®cial effect in these
patients by reducing tumour-induced oedema formation.
Furthermore, during stroke, oedema formation occurring
around infarcted brain tissue was signi®cantly reduced by the
fusion protein mFlt(1-3)±IgG, which sequesters VEGF (van
Bruggen et al., 1999). Recent data demonstrated that Src
family kinases are involved in the VEGF-mediated augmen-
tation of vascular permeability (Eliceiri et al., 1999).
Blockade of Src activity in mice provided cerebral protection
following stroke due to reduced brain oedema formation
(Paul et al., 2001). Our results are in line with these reports
and now suggest that blocking VEGF action may be a more
speci®c therapeutic approach to the treatment of HACE. This
notion is further sustained by the recent ®nding that
dexamethasone, which is widely used at high altitude as
well as in the clinic to reduce cerebral oedema, is capable of
inhibiting hypoxia-induced VEGF gene expression (Heiss
et al., 1996; Fischer et al., 2001).
Putative mechanisms involved in VEGF-
mediated vascular permeability
It has been shown both in vitro (Fischer et al., 1999) and
in vivo (Mayhan, 1999) that the VEGF-mediated increase in
permeability of the BBB involves nitric oxide- and cGMP
(cyclic guanosine monophosphate)-dependent pathways. It
remains unclear, however, where these molecules exert their
action. It has been hypothesized that VEGF may induce the
opening of interendothelial tight junctions or change the
endothelial cell phenotype, or even alter pinocytic transport
through the endothelial cell (Mayhan, 2001). On the one
hand, topical administration or intradermal injection of
VEGF can transform continuous endothelium into fenestrated
endothelium and thereby increase vascular permeability
(Roberts and Palade, 1995). On the other hand, BBB
permeability may be controlled by phosphorylation of tight-
junction proteins (Papadopoulos et al., 2001). For example,
occludin and zonula occludens 1 (ZO-1), which are both
important constituents of the tight junction, are rapidly
phosphorylated by VEGF treatment (Antonetti et al., 1999).
Furthermore, VEGF reduced occludin expression and dis-
rupted both ZO-1 and occludin organization at the tight
junction (Wang et al., 2001). In an in vitro model of the BBB,
we have recently shown that hypoxia-induced hyperperme-
ability involves changes in the expression of ZO-1 and that
these changes are mediated by VEGF (Fischer et al., 2002).
Taken together, these results suggest that alteration of tight-
junction protein expression and phosphorylation may regulate
vascular permeability.
Future research, including the generation and analysis of
mice with inducible overexpression of VEGF under the
control of brain-speci®c promoters, will help us to understand
fully the mechanisms whereby VEGF induces permeability
and to unravel the different effects of VEGF in the CNS
involving angiogenesis, permeability induction and neuro-
protection. In summary, we have shown that hypoxia-induced
VEGF expression in the brain is responsible for vascular
leakage. These ®ndings provide the background for the
development of therapeutic strategies to treat HACE based on
the inhibition of VEGF action.
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